Home Bratislava Medical Journal 2013 Bratislava Medical Journal Vol.114, No.2, p.50–52, 2013

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.2

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.114, No.2, p.50–52, 2013

Title: Mesenchymal stem cells – a promising perspective in the orofacial cleft surgery
Author: P. Stanko, J. Mracna, A. Stebel, V. Usakova, M. Smrekova, J. Vojtassak

Abstract: Autologous bone grafts provide the golden standard for closure of oronasal fistulas in the cleft palate. Augmentation may be performed also by homografts and various xenogenic or alloplastic materials to prevent morbidity at the donor site but they may cause many problems (transmission of infections, immune response etc.). All the mentioned approaches also often reveal recurrences of the fistulas and prolong suffering of the cleft patients. Combination of mesenchymal stem cells (MSCs) and so called “platelet gel” seems to be a perspective method in this way. The platelet gel contains hydroxyapatite particles mixed with platelet rich plasma coagulated under effect of the calcium ions. The MSCs from the pelvic bone marrow aspirate are cultivated on a scaffold (collagen membrane) for 3–4 weeks before placement into the cleft defect. The method provides promising results in the alveolar clefts. Authors document a successful case of the secondary surgery in 25-year-old man with the unilateral complete cleft (Fig. 5, Ref. 10).

Keywords: cleft palate, oronasal fistula, mesenchymal stem cells, platelet rich plasma, hydroxyapatite
Year: 2013, Volume: 114, Issue: 2 Page From: 50, Page To: 52
doi:10.4149/BLL_2013_012


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.